USPTO issues patent for Lavengel® product that is used against skin infections
RTD Neutraceuticals LLC of Johnson City has been issued a U.S. patent for its Lavengel® product that is used against skin infections caused by Staphylococcus bacteria.
The patent, titled “Topical Gel Compositions for the Treatment of Staphylococcal Infections,” is for the technology invented by W. Andrew Clark, Chief Technology Officer of the company, and Associate Dean of Research at East Tennessee State University’s College of Clinical and Rehabilitative Health Sciences.
“We continue to be surprised about the efficacy of Lavengel® in resolving skin issues in humans and animals,” says Clark, “and have seen effectiveness with insect bites, abrasions, burns, blisters, disrupted skin from radiation, eczema, ‘hot spots’ in dogs, cuts, cold sores, incision lines, MRSA/MRSP infections and numerous others.” Lavengel® is available to the public online at lavengel.com as well as on Amazon.com and smartworldmarket.com. It is also found in selected retail stores in the region.
We spotlighted Clark in this April 2017 article in teknovation.biz, and the Johnson City Press ran this article on RTD Neutraceuticals last July.
